Abstract:Alzheimer’s disease (AD) is a progressive neurodegenerative disease, resulting in an irreversible deterioration of multiple brain regions associated with cognitive dysfunction. Phosphorylation of the microtubule-associated protein, Tau, is known to occur decades before symptomatic AD. The Src family of tyrosine kinases are known to phosphorylate select tyrosine sites on Tau and promote microtubule disassembly and subsequent neurofibrillary tangle (NFT) formation. Our data show that the proto-oncogene, non-receptor tyrosine kinase Src colocalizes with a range of late (PHF1) to early (MC1) AD-associated phosphorylated Tau epitopes. The strongest co-occurrence is seen with MC1 (probability of MC1 given Src =100%), an early AD-specific conformational dependent epitope. Single-cell RNA sequencing data of 101 subjects show that is upregulated in both AD inhibitory and excitatory neurons. The most significantly affected, by orders of magnitude, were excitatory neurons which are the most prone to pathological Tau accumulation. We measured Src phosphorylation by mass spectrometry across a cohort of 48 patient neocortical tissues and found that Src has increased phosphorylation on Ser75, Tyr187, and Tyr440 in AD, showing that Src kinase undergoes distinct phosphorylation alterations in AD. Through Brownian dynamics simulations of Src and Tau, we show that as Tau undergoes the transition into disease-associated paired helical filaments, there is a notable seven-fold increase in Src contact with Tau. These results collectively emphasize Src kinase’s central role in Tau phosphorylation and its close association with Tau epitopes, presenting a promising target for potential therapeutic intervention.

What problem does this paper attempt to address?

The paper primarily explores the role of Src kinase in Alzheimer's disease (AD) and its potential therapeutic significance. Specifically, the paper attempts to address the following key questions: 1. **The relationship between Src kinase and Tau protein**: Whether Src family tyrosine kinases are involved in the phosphorylation process of Tau protein and promote the formation of neurofibrillary tangles (NFT). 2. **Expression changes of Src kinase in AD**: Whether Src kinase is upregulated in the brains of AD patients, and if this upregulation is associated with specific types of neurons. 3. **Changes in the phosphorylation state of Src kinase**: Whether Src kinase in AD patients undergoes specific phosphorylation changes and if these changes are related to the disease progression. 4. **Mechanism of interaction between Src kinase and Tau protein**: Simulating the interaction patterns between Src kinase and Tau protein under normal and disease conditions. Key findings of the paper include: - Src kinase co-localizes with multiple AD-related phosphorylated Tau epitopes, with the most significant co-localization observed with the early AD marker MC1. - Single-cell RNA sequencing data show that Src kinase is upregulated in both inhibitory and excitatory neurons of AD patients, with the upregulation being most pronounced in excitatory neurons. - Mass spectrometry analysis reveals elevated phosphorylation levels of Src kinase at Ser75, Tyr187, and Tyr440 sites in the brains of AD patients. - Simulation studies indicate that as Tau protein transitions to disease-associated paired helical filaments (PHF), the contact between Src kinase and Tau protein significantly increases. In summary, the paper reveals the important role of Src kinase in the pathogenesis of AD and suggests that Src kinase could be a potential target for AD therapy.

Upregulation of the Proto-Oncogene Src Kinase in Alzheimer’s Disease: From Molecular Interactions to Therapeutic Potential

Impaired Src signaling and post-synaptic actin polymerization in Alzheimer's disease mice hippocampus--linking NMDA receptors and the reelin pathway

Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer’s disease

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer’s disease

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP

Targeting Abnormal Tau Phosphorylation for Alzheimer's Therapeutics

Delta-Secretase Phosphorylation by SRPK2 Enhances Its Enzymatic Activity, Provoking Pathogenesis in Alzheimer's Disease

Angiotensin-(1-7) is Reduced and Inversely Correlates with Tau Hyperphosphorylation in Animal Models of Alzheimer’s Disease

Uncovering elevated tau TPP motif phosphorylation in the brain of Alzheimer's disease patients

A cell autonomous regulator of neuronal excitability modulates tau in Alzheimer's disease vulnerable neurons

Selective Degradation of Hyperphosphorylated Tau by Proteolysis-Targeting Chimeras Ameliorates Cognitive Function in Alzheimer’s Disease Model Mice

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

C-Src Regulates Δ-Secretase Activation and Truncated Tau Production by Phosphorylating the E3 Ligase Traf6.

Fyn Kinase in Alzheimer's Disease: Unraveling Molecular Mechanisms and Therapeutic Implications

Modulation of neuronal thread protein expression with neuritic sprouting: relevance to Alzheimer's disease

Super-Resolution Imaging Uncovers Nanoscale Tau Aggregate Hyperphosphorylation Patterns in Human Alzheimer’s Disease Brain Tissue

Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer's disease model mice

RAB10 PHOSPHORYLATION IS A PROMINENT PATHOLOGICAL FEATURE IN ALZHEIMER’S DISEASE

5-Hydroxymethylation-associated epigenetic modifiers of Alzheimer's disease modulate Tau-induced neurotoxicity

P3‐437: RAB10 PHOSPHORYLATION IS A PROMINENT PATHOLOGICAL FEATURE IN ALZHEIMER'S DISEASE